Yellow fever vaccine

A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunity

“…In addition, there is a solid body of evidence that the clearance of LASV and recovery of LF patients is not dependent on antibody responses but is associated with cell-mediated immunity [7,8]. Live replicationcompetent vaccines elicit strong cellular immune responses, confer long-term protection after a single injection, and have low manufacturing costs [9]. Two vaccines recently licensed by the FDA, FluMist (MedImmune Vaccines, Inc.) and RotaTeq (Merck & Co.), are live attenuated vaccines based on reassortant technology.…”

“…Death or survival past 21 days was set up as an endpoint. Amino acid difference between LASV-Jo and LASV-803213 is the highest within LASV genetic lineages I-IV(9).b Non applicable.…”

Yellow Fever Encephalitis: An Emerging and Resurging Global Public Health Threat in a Changing Environment

“…Clinical diagnosis of yellow fever is possible when the pathognomonic features of biphasic/ triphasic acute illness and typical clinical features occur in unvaccinated individuals with a compatible exposure history. Unfortunately, these features are present only in a minority of patients [67]. Laboratory confirmation of YF is pivotal to diagnosis, but unfortunately requires highly trained laboratory staff with access to specialized equipment and materials.…”

“…Yellow fever (YF) is one of the great infectious scourges of humankind. It is a zoonosis indigenous to some tropical regions of South America and Africa which has caused numerous epidemics with high mortality rates throughout history [2]. Approximately 200,000 cases of YF occur annually, resulting in about 30 000 deaths; 90% of cases occur in Africa.…”

“…YFV is endemically transmitted in forests and savannas of South America and Africa, periodically emerging from enzootic cycles to cause epidemics of hemorrhagic fever [2],with reported fatality rates ranging from 20% to 80% due to two principal syndromes: YEL-AND (yellow-fever associated neurologic disease, which includes encephalitis, myelitis or myelo-In East Africa, yellow fever remains as a disease of increasing epidemic risk. The most recent yellow fever outbreak in the region was reported by the WHO in the late 2010 and included the first human cases reported in Uganda in almost 50 years [11].…”